Clinical trials
Lung Cancer Stage I clinical trials
Below are recruiting lung cancer stage i clinical trials, each written for real people, not researchers. We’re tracking 1,138 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05703971RecruitingPhase 1/Phase 2
Maintenance treatment with a gene therapy plus atezolizumab
This Phase 1/2 trial tests whether a gene therapy called Reqorsa given with atezolizumab can help people with extensive-stage small cell lung cancer (ES-SCLC) stay controlled after their first chemo. It may help by boosting the immune system to keep the cancer from growing again.
Lone Tree, ColoradoAges 18 years+ - NCT06030258RecruitingPhase 1/Phase 2
Study of IN10018 plus standard chemo for extensive-stage small cell lung cancer
This trial tests a new drug called IN10018 combined with standard chemotherapy (carboplatin and etoposide) and an immunotherapy (anti-PD-1/L1) for people with extensive-stage small cell lung cancer (ES-SCLC) who have not yet been treated. The goal is to see if adding IN10018 helps shrink tumors or slow the cancer's growth.
JinanAges 18–75 - NCT05745350RecruitingPhase 2
First treatment for extensive-stage small cell lung cancer
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06348797RecruitingPhase 1
CAR-T Cells Targeting PD-L1 and DLL3 for Small Cell Lung Cancer
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
Chengdu, SichuanAges 18–70 - NCT05255302RecruitingPhase 2/Phase 3
Shorter immune maintenance for stage IV lung cancer after initial treatment
This trial tests whether giving immune therapy maintenance for a shorter time helps people with stage IV non-small cell lung cancer (NSCLC) who are doing well after initial chemo-immunotherapy. It aims to keep the cancer controlled while possibly reducing treatment exposure and side effects.
Aix-en-ProvenceAges 18–74 - NCT06532149Recruiting
Sexual health and erectile function in men with lung cancer
This study looks at how lung cancer and its treatments affect men's sexual health, including erectile function and hormone levels. If you are a man with advanced lung cancer and are sexually active, researchers want to learn about your experiences and test results.
RomeAges 18–75 - NCT06749691RecruitingPhase 2
Liposomal irinotecan and apatinib for extensive-stage small cell lung cancer
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT07055581RecruitingPhase 2
Durvalumab after initial treatment for limited-stage lung cancer
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
Zhengzhou, HenanAges 18 years+ - NCT06648317Recruiting
New PET scan for lung tumors using a Nectin-4 probe
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT07116057RecruitingPhase 1
CAR T cell therapy for FRa-positive cancers
This trial tests a new treatment called MOv19-BBz CAR T cells, which are specially designed immune cells that target a protein called FRa found on some cancer cells. It's for people with advanced lung cancer that has spread to the lining of the lung (malignant pleural effusion) and who have already tried at least one standard treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT07590531RecruitingPhase 1/Phase 2
Two-Drug Lung Cancer Treatment Study
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT05416775RecruitingPhase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
Hefei, AnhuiAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT04980716RecruitingPhase 3
Heart-based early intervention for stage III lung cancer using heart signals
This trial tests an early heart-focused intervention guided by a special heart recording (impedance cardiography) in people with locally advanced, unresectable stage III non-small cell lung cancer. The goal is to improve heart-related safety during planned radiation and chemotherapy, with or without immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT06071013RecruitingPhase 1/Phase 2
Nintedanib plus EGFR inhibitor for EGFR-mutated lung cancer
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
TaichungAges 20–70 - NCT06330038RecruitingPhase 4
Anesthesia type and lung cancer return after surgery
This study looks at whether the type of anesthesia you receive during lung cancer surgery may affect the chance of your cancer coming back. It is for people with non-small cell lung cancer who are having surgery to remove the tumor.
Seoul, Seoul-teukbyeolsiAges 19 years+ - NCT06684418Recruiting
AI to find hidden cancer spread in early lung cancer
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
ShanghaiAges 18 years+ - NCT06693336RecruitingPhase 2
Adjuvant chemotherapy trial for early-stage lung cancer
This trial tests a chemotherapy drug called SMS001 (a form of paclitaxel) after surgery for non-small cell lung cancer. It may help prevent the cancer from coming back.
Rochester, MinnesotaAges 18–80 - NCT06718309RecruitingPhase 2
Chemo and immunotherapy with targeted radiation before surgery for lung cancer
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hangzhou, ZhejiangAges 18 years+ - NCT06980272RecruitingPhase 3
A new drug for advanced lung cancer that hasn't been treated yet
This trial tests a new drug called SSGJ-707 for people with advanced non-small cell lung cancer who have not had prior treatment. It aims to see if the drug can help shrink tumors and improve outcomes.
ShanghaiAges 18 years+
Hear when a new Lung Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage i?
- Yes. Clin2 currently lists 1,138 recruiting lung cancer stage i studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage i trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage i trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.